TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05568680: SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

Sponsor: Verismo Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 42 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$848,232

Rescue Site Savings

+$565,488

Unlock Full NCT05568680 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05568680 Rescue Dossier →